Keyphrases
18F-FDG PET-CT
50%
Zirconium-89 (89Zr)
50%
Metastatic Renal Cell Carcinoma (mRCC)
50%
Waiting Period
50%
Girentuximab
50%
Watchful Waiting
50%
Cancer Molecular Imaging
50%
Metastatic Breast Cancer
50%
Whole-body
50%
Human Epidermal Growth Factor Receptor 2 (HER2)
50%
Human Epidermal Growth Factor Receptor 2-negative
50%
Understanding of Cancer
25%
Immunohistochemistry
21%
Metastasis
17%
SUVmax
17%
18F-fluorodeoxyglucose (18F-FDG)
15%
Low Uptake
15%
Positron Emission Tomography-computed Tomography (PET-CT)
15%
89Zr-trastuzumab
14%
FDG Uptake
10%
Tumor Uptake
10%
Predictive Value
10%
Geometric Mean
8%
HER2-positive BC
7%
Diagnostic Performance
7%
Standardized Uptake Value
5%
Metastatic Site
5%
Waiting Time
5%
Intermediate Prognosis
5%
Response Evaluation Criteria in Solid Tumors (RECIST)
5%
CT Images
5%
Disease Progression
5%
Good Prognosis
5%
BECTS
5%
Systemic Treatment
5%
Watch-and-wait
5%
Intermediate Risk
5%
Metastatic RCC
5%
Medicine and Dentistry
Fluorodeoxyglucose F 18
100%
Neoplasm
60%
Positron Emission Tomography-Computed Tomography
58%
Molecular Imaging
50%
Clear Cell Renal Cell Carcinoma
50%
Malignant Neoplasm
50%
Girentuximab
50%
Watchful Waiting
50%
Metastatic Carcinoma
50%
Metastatic Breast Cancer
50%
Zirconium 89
50%
Oncology
33%
Anticarcinogen
16%
Single-Photon Emission Computed Tomography
16%
Radioisotope
16%
Positron Emission Tomography
16%
Clinical Trial
16%
Positron Emission Tomography
12%
Standardized Uptake Value
9%
Lobular Carcinoma
8%
Biopsy
8%
Tumor Biopsy
8%
Disease Exacerbation
5%
Systemic Therapy
5%
